Bispecific ADC
“Built to Wait. Wired to Strike.”
Conditionally active payloads that engage only when the environment is right.
Epitope-Based Masked ADC: A Smarter Way to Deliver Cytotoxicity
Antibody-drug conjugates have revolutionized cancer therapy by enabling targeted delivery of potent cytotoxins. However, off-tumor toxicity remains a significant limitation, even for tumor-associated target antigens like MUC1 or Cathepsin B enriched in the TME.
Our epitope-based masking technology addresses this challenge by engineering a maskable peptide epitope that naturally blocks the antigen-binding site of the antibody until removed by tumor microenvironment (TME), while proteases cleave the mask and expose the active binding site.
How It Works:
Masking Peptide
Designed to specifically cover the epitope region of the antibody.
Tumor-Specific Cleavage
Cleaved by proteases like MMP2/9 or Cathepsin B enriched in the TME.
Reactivated Binding
Once unmasked, the antibody binds its tumor antigen with full affinity.
Payload Delivery
Internalization and intracellular payload release follow naturally.